Document:

EXECUTIVE EMPLOYMENT AGREEMENT, DATED AS OF FEBRUARY 19, 2003

 Exhibit 4.12 
  
 Mark C. Rogers, MD MBA 
 Chairman of the Board of Directors 
  
 February
19, 2003 
  
 William P. Peters MD, PhD 
 2872 Chestnut Run Drive 
 Bloomfield Hills, Michigan 48302 
  
 Dear Dr. Peters: 
  
 As Chairman of the Board of Directors of Adherex Technologies Inc and its US subsidiary Adherex, Inc. and on behalf on the Compensation
Committee of the Board, it is my pleasure to offer you (“you” or ‘Peters’) the position of Chief Executive Officer and Vice Chairman of Adherex Technologies Inc (‘Corporation’, ‘Company’ or
‘Adherex’) on the terms contained herein. 
  
 1. Position and
Obligations Description: 
  

	 	•	You will be appointed Chief Executive Officer and Vice Chairman effective March 12, 2003 for a five year term ending March 11, 2008, unless terminated earlier pursuant to the terms
hereof. As Chief Executive Officer and Vice Chairman you shall have, subject always to the general direction, approval, and control of the Board of Directors of the Corporation (‘Board’), the power and authority to manage and direct the
business and affairs of the Corporation (except only the matters and duties: (i) as by law or by the rules and policies of any stock exchange on which the Company’s shares are listed must be transacted or performed by the Board or by the
shareholders of the Corporation in a general or special meeting; or (ii) that, by the Company’s policies respecting corporate governance as established by the Board, must be transacted or performed by the Board or a committee thereof),
including setting strategic direction, the power and authority to enter into contracts, engagements or commitments of every nature or kind in the name of and on behalf of the Corporation, for formulating and administering policies, for personnel
decisions concerning hiring and/or retention, and other usual authorities and responsibilities of the Chief Executive Officer. 

  

	 	•	In the role of Chief Executive Officer and Vice Chairman, you will faithfully serve the Corporation and its subsidiaries and use your best efforts to promote the interests thereof,
conform to all lawful instructions and directions given to you by the Board and obey and carry out the by-laws of the Corporation, and devote your full time and attention to perform the duties of the position. Notwithstanding the foregoing, you may
request in writing to the Chairman of the Board any other material, executive level, duties in either not-for-profit or for-profit organizations not related to the Corporation and secure the approval of the Board of Directors prior to undertaking
any such duties. 

  

					
	 Confidential
	 	Page 1	 	 

	 	•	You will continue your position as a director of the Corporation as approved on November 5, 2002 at the annual and special meeting of the shareholders of the Corporation.

  
 2. Compensation: 
  

	 	•	Salary: You will receive a salary in the amount of $350,000US per year for performance of the Chief Executive Officer services specified in this Agreement in the first year. For
subsequent years, you shall receive such increases, if any, as may be agreed to by the Board. All salary payments will be subject to applicable statutory deductions. 

  

	 	•	Signing Bonus: The Company will pay you a signing bonus totaling $200,000US to be paid as $40,000US at time of signing and $80,000US on July 1, 2003, and $80,000US on September 1,
2003. All signing bonus payments will be subject to applicable statutory deductions. 

  

	 	•	Annual Bonus: Subject to the satisfactory achievement of agreed upon goals (as set forth in the attached Exhibit C), you will receive an annual bonus of up to 50% of your annual
salary and additional stock options as determined in the sole discretion of Board. All annual bonus payments will be subject to applicable statutory deductions. 

  

	 	•	Initial Incentive Bonus: In addition, the Company will grant to you additional stock options to be determined upon the completion by the Company of a financing through the sale of
equity securities of at least US$ 3.75 million or a contract with a strategic partner which invests US$ 3.75 million with the Company.  

  

	 	•	Long Term Incentive (LTI): At the time of signing of this Agreement, you will be granted an option to purchase 3.75 million Adherex common stock (CUSIP # 00686R) exercisable at
market price (‘LTI Options’). The market price will be as defined in the Corporation’s Employee Stock Option Plan (‘ESOP’) and the options will be granted pursuant to the ESOP.  

  

	 	•	Option term: The duration of the LTI Options and the Initial Incentive Bonus options will be seven (7) years.  

  

	 	•	Lock-out period: You will be restricted from selling any common stock of the Corporation during the Lockout Term as defined in that certain agreement between you and the Corporation
dated November 14, 2002 and during any “blackout periods” that apply, at the time of such sale, to all insiders of the Company. You may further be required to comply with other restrictions on the sale of Company stock which the Board may
impose on all insiders of the Company.  

  

	 	•	Vesting: One third of the LTI Options shall vest immediately upon granting of the said options to you. Another third of the LTI Options shall vest on the next day following the one
year anniversary of the granting of 

  

					
	 Confidential
	 	Page 2	 	 

 the said options to you. The last third of the LTI Options shall vest on the next day following the two
year anniversary of the granting of the said options to you. 
  

	 	•	The total of the LTI Options and the Initial Incentive Bonus stock options shall be equal to 5% of the fully diluted outstanding common stock of the Corporation immediately
following the closing of the US $3.75 million transaction referenced above. To the extent required by the rules and policies of the Toronto Stock Exchange, the Initial Incentive Bonus stock option grant shall be subject to and conditional upon
regulatory and shareholder approval. Adherex shall seek any shareholder approval at the next meeting of shareholders and otherwise apply to any regulatory agency and take such further reasonable steps to support such application or obtain such
shareholder approval.  

  

	 	•	All other terms of the LTI Options and the Initial Incentive Bonus stock options will be as set out in the ESOP and Stock Option Agreement which shall be executed in the form set
out in the ESOP . 

  

	 	•	The Company shall cause its US wholly owned subsidiary Adherex Inc. to directly employ you in order to enable the continuation of your current status as a US resident and taxpayer
and the orderly remittance of statutory deductions directly to the appropriate US taxing authorities.  

  

	 	•	Benefits: 

  

	 	•	You and your immediate family will be provided with comprehensive medical and prescription plans, dental, and disability insurance pursuant to the benefit plans which the
Corporation provides to its executives from time to time in Canada and the United States, including medical/hospital and extended care benefits and life insurance. During the first year of your employment, the Corporation will reimburse you for
continuation of your current comprehensive medical, dental and prescription plan as provided under COBRA. You will be entitled to five weeks paid vacation, up to 2 weeks of which may be accrued into the next year if not completely utilized in the
current year. The Corporation will pay your malpractice insurance premium up to $10,000 per year. 

  

	 	•	Relocation: The Board will consider relocation of the Corporation’s headquarters to the US in the first year of your term as Chief Executive Officer. In order to mitigate the
inconvenience and expense of two relocations, and pending this relocation discussion and its resolution by the Board, you will be entitled to reimbursement for all reasonable pre-approved transportation expenses between your residences in Michigan
or Florida to Adherex’s offices in Ottawa, and associated hotel/apartment and ground transportation costs until Adherex relocates its headquarters to its new, presently undesignated, location. Following the Relocation, Adherex will provide you
with pre-approved relocation assistance as described in Exhibit “A” to this Agreement. 

  

					
	 Confidential
	 	Page 3	 	 

	 	•	Expense account: You will be entitled to reimbursement for all reasonable business expenses incurred in the performance of your duties upon presentation of a voucher indicating the
amount and business purpose. 

  
 3. Termination and/or Change of
Control Provisions 
  
 In the event that Adherex terminates you without Cause
or you terminate your employment for Good Reason or a Change of Control, you shall be paid an amount equal to 24 months of the then current Salary plus earned vacation pay, earned bonus, COBRA and earned benefits due as of the termination date. This
sum is to be paid within 30 days following said termination and will be subject to all statutory deductions. For purposes of this Agreement the terms “Cause”, “Change of Control” and “Good Reason” are defined in Exhibit
“B” to this Agreement. At the time of payment by the Company of the required amount under this paragraph the parties shall exchange full and final mutual releases in a form acceptable to the parties. 
  
 If your employment is terminated by reason of your death, your estate shall be entitled to
receive benefits in a manner consistent with and at least equal in amount to those provided by the Corporation and its subsidiaries to surviving families of the senior executives of the Corporation and its subsidiaries under such plans, programs and
policies relating to family death benefits, if any, as are in effect at the date of your death. 
  
 If your employment is terminated by the Board for Cause, then the Company shall pay you your base Salary through the date of your termination and you shall have no further entitlement to any other compensation or
benefits from the Company. All stock options that have not vested as of the date of termination shall expire pursuant to the ESOP plan. 
  
 The Company shall cause you to be elected as a member of its Board throughout the Term and shall include you in the management slate for election as a director at every
shareholders’ meeting during the Term at which your term as a director would otherwise expire. You agree to accept election, and to serve during the Term, as director of the Company, without any additional compensation beyond that specified in
this Agreement. 
  
 The term of this agreement will automatically renew for a
period of two years from the last day of the then current term if you are not advised in writing to the contrary by the Company on or before the beginning of the last year of the then current term (which shall be March 11, 2007 with respect to this
first term), and if you are so advised that this agreement will not be renewed, you will continue to receive the salary, bonuses and benefits payable to you in the ordinary course under this Agreement during and until the end of such last year of
the then current term, and no more. 
  

					
	 Confidential
	 	Page 4	 	 

 4. Non-compete and Confidentiality 
  
 You will not, either individually or in partnership or jointly or in conjunction with any person or persons, firm, association, syndicate,
company or corporation, as principal, agent, shareholder or in any other manner, engage in the commercial drug development of chemoprotectants and/or chemoenhancers and/or cadherin antagonists for a period of six months if your voluntarily cease
your employment, you cease employment for Good Reason or Change of Control, or if the Company terminates you without Cause, or for a period of 24 months if you are terminated by the Company for Cause (the applicable period, the “Restricted
Period”). Nothing herein shall restrict or prevent you from owning as a passive investor less than 5% of any class of securities of a corporation or entity which is a competitor of the Corporation’s whose securities are trading in the
public market, or less than 5% of any class of securities of a corporation or entity which is not a direct competitor of any of the Corporation, whether or not such corporation’s or entity’s securities are trading in the public market. You
will not at any time within the Restricted Period, directly or indirectly, approach or solicit any employee of the Corporation. 
  
 You agree to keep confidential certain information of the Company as set out in Exhibit D to this agreement. 
  
 By signing this Agreement, you represent and warrant to the Company that neither the execution or delivery of this Agreement nor the
performance by you of your duties and other obligations hereunder: (i) constitute a violation or default under any order or judgment against you; (ii) conflict with or constitute a default or breach of any covenant or obligation (whether
immediately, upon the giving of notice or lapse of time or both) under any prior employment agreement, contract, or other instrument to which you are a party or by which you are bound; or (iii) require you to obtain any approval or consent of any
third party. 
  
 5. General Provisions 
  
 A. Validity. If a court of competent jurisdiction deems any provision
of this Agreement invalid, such provision shall be deemed not to be a part of this Agreement, and shall not affect the validity or enforceability of the remaining provisions; 
  
 B. Assignment. Peters acknowledges that his services are unique and personal. Accordingly, Peters may not assign his
rights or delegate his duties hereunder. Adherex’s rights and obligations under this Agreement shall inure to the benefit of, and shall be binding upon, Adherex’s successors and assigns. 
  

					
	 Confidential
	 	Page 5	 	 

 C. Notices. Any notice required or desired to be given under this Agreement shall be deemed given
only if in writing and sent by certified mail, return receipt requested, to Peters’ residence or to Adherex’s principle office, as the case may be. 
  
 D. Headings. Headings in this Agreement are for convenience only and shall not be used to interpret or construe its provisions. 
  
 E. Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
  
 F. Governing Law. This Agreement shall be governed by and construed under the laws of the State of Michigan and the United States of America until
such time as the Company re-locates to the United States, at which time, upon our mutual agreement, this Agreement may be governed by and construed under the laws of the state in which the Company is headquartered. 
  
 G. Arm’s Length. This Agreement has been negotiated at arms
length and each party has been represented by legal counsel or has had the opportunity to be represented by legal counsel. Accordingly, the rule of law or legal decision that would require the interpretation of any ambiguities in this Agreement
against the party drafting it is not applicable and is, therefore, waived. 
  
 H. Amendment and Waiver. No supplement, modification, amendment or waiver of this Agreement shall be binding unless executed in writing by both parties. No waiver of any of the provisions of this Agreement
shall constitute a waiver of any other provision (whether or not similar) nor shall such waiver constitute a continuing waiver unless otherwise expressly provided. 
  
 I. Survival. Notwithstanding the termination of this Agreement, (a) neither party shall be released from any
obligation that accrued prior to the date of termination; and (b) each party shall remain bound by the provisions of this Agreement which by their terms impose obligations upon that party that extend beyond the termination of this Agreement.

  
 If you are willing to accept the position of Chief Executive
Officer and Vice Chairman of Adherex under the terms and conditions described in this letter, acknowledge this by signing both copies of the letter, returning one copy to me by certified mail. 
  
 Sincerely yours, 
  

	
	 /s/ Mark C. Rogers

	 Mark C. Rogers, MD, MBA

	 Chairman of the Board

	 Adherex Technologies Inc.

  

					
	 Confidential
	 	Page 6	 	 

 Acknowledged and accepted: 
  

			
	 /s/ William P. Peters

	 	 
	 William P. Peters, MD PhD
	 	Date: 2/19/03

  

					
			
	 Witnesses:
	 	 /s/ Leslie M. Trumble

	 	 Date: 2/19/03

  

					
	 Confidential
	 	Page 7	 	 

 Exhibit A: Relocation Assistance 
  

Adherex will provide Peters with the following relocation assistance. This assistance is to minimize the inconvenience Peters and his family may
experience as a result of moving from their present home to a new community. 
  
 In connection with Peters’ relocation, Adherex will reimburse Peters for the following: 
  
 1. Usual and customary expenses incurred if Peters sells his home himself or through a broker; however, reimbursement for the
broker’s commission may not exceed the lower of (a) a six (6) percent broker’s commission on the sale of the property and (b) the actual broker’s commission. 
  
 2. Reasonable expenses incurred in moving furniture, normal household goods and autos, academic office and
personal belongings to the new location. 
  
 3.
Reasonable expenses incurred while house hunting, including two (2) trips to the new location with Peters’ spouse. 
  
 4. Reasonable and customary closing costs incurred in buying the new home; however, the amount to be reimbursed shall not exceed Five
Thousand 00/100 Dollars ($5,000)US. 
  
 5.
Reasonable temporary living expenses incurred while awaiting occupancy of the new residence to the extent Peters’ present residence is sold, leased, or otherwise unable to be occupied. 
  
 6. Incidental expenses related to a move which are not
addressed elsewhere in this Exhibit; however, the amount to be reimbursed shall not exceed Two Thousand 00/100 Dollars ($2,000)US. 
  

					
	 Confidential
	 	 	 	 

 Exhibit B: Definitions of Key Terms 
  
 (i) “Cause” shall mean: 
  
 (a) Your conviction of (i) any felony or (ii) any misdemeanor involving sexual misconduct, fraud, or
embezzlement (other than a traffic infraction); 
  
 (b) Your willful misconduct with regard to your duties and responsibilities; or 
  
 (c) Gross negligence (other than as a result of physical or mental impairment) with regard to his duties. 
  
 (d) Your material breach of this agreement. 
  
 (e) In the case of (b) and/or (c) and/or (d) above, Cause
shall not be established unless and until Peters fails to cure such misconduct, breach, or negligence (if capable of being cured) within a period of twenty (20) days from receiving written notice from Adherex of its intent to terminate Peters’
employment for Cause as a result of such circumstances, which notice describes such circumstance with sufficient particularity to give Peters a reasonable opportunity to resolve or cure any such misconduct, breach, or negligence (if capable of being
cured). 
  
 “Good Reason” shall include,
without limitation, the occurrence of any of the following without Peters’ written consent: 
  

	 	(i)	a change (other than those that are clearly consistent with a promotion) in Peters’ position or duties (including any position or duties as a director of the Corporation),
responsibilities (including, without limitation, to whom Peters reports and who reports to Peters), title or office, which includes any removal of Peters from or any failure to re-elect or re-appoint Peters to any such position or offices;

  

	 	(ii)	a reduction by the Corporation or any of its subsidiaries of Peters’ Salary, Benefits or any change in the basis upon which Peters’ Salary or Benefits payable by the
Corporation or its subsidiaries is determined which is not consented to by Peters and which does not apply equally to all employees of the Corporation; 

  

	 	(iii)	any breach by the Corporation of any provision of this Agreement; 

  

					
	 Confidential
	 	 	 	 

	 	(iv)	after a Change of Control: (a) The Board repeatedly overrides, supersedes, or disregards reasonable decisions by you or recommendations made by you to the Board, such that the Board
materially interferes with your ability to effectively function as the Chief Executive Officer, or (b) the Board otherwise takes actions that constructively represent a lack of confidence in your ability to perform your duties and responsibilities;

  
 provided, that in all cases, such action or
breach is not resolved or cured within thirty (30) days following your written notice to Adherex of the event that you assert is the basis for Good Reason, and which event or behavior Adherex does not resolve or cure during such thirty (30) day
period. 
  
 “Change of Control” shall
mean the acquisition (at one time or over a period of time) of shares of the Corporation or of securities (“Convertible Securities”) convertible into, exchangeable for or representing the right to acquire shares of the Corporation as a
result of which a person, group of persons or persons acting jointly or in a concert, or persons associated or affiliated within the meaning of the Business Corporation Act (Ontario) with any such person, group of persons or persons acting jointly
or in concert (collectively, the “Acquirors”), beneficially own shares of the Corporation and/or Convertible Securities that would entitle the holders thereof to cast more than 50% of the votes attaching to all shares in the capital of the
Corporation that may cast to elect directors of the Corporation (assuming the conversion, exchange or exercise of Convertible Securities beneficially owned by the Acquirors). For the avoidance of doubt, a Change of Control shall not include a
reverse takeover or other reorganization whereby the holders of shares and Convertible Securities of the Corporation immediately prior to such transaction beneficially own, following the completion of the transaction, shares of the parent or
surviving corporation that would entitle the holders thereof to cast more than 50% of the votes attaching to all shares in the capital of such parent or surviving corporation that may cast to elect directors of such parent or surviving corporation.

  

					
	 Confidential
	 	 	 	 

 Exhibit C: Objectives for Annual Incentive Bonus 
  
 2003: Objectives: Maximum annual bonus in 2003 is 50% of base salary ($175,000); each of the following will be considered as independent
criterion in establishing short term incentive bonus. 
  

				
	 Objective

	  	Bonus Amount

	 Initiate US Phase I Exherin Trial
	  	$	20,000
	 Initiate Phase I/II Mesna Trial
	  	$	15,000
	 Initiate Phase III STS Trial
	  	$	15,000
	 Achieve Board approval for product development strategy
	  	$	25,000
	 Submit Orphan Drug Application for STS
	  	$	15,000
	 Evaluate and achieve Board approval for US location
	  	$	10,000
	 Finish Canadian Phase I Exherin Trial
	  	$	20,000
	 Secure second $3.75 million in financing
	  	$	20,000
	 Stock price exceeds $1 for at least one day (3x current price)
	  	$	25,000
	 Other board objectives and assessment of performance
	  	$	75,000

  
 2004 Objectives: Maximum annual bonus
in 2004 is 50% of base salary ($175,000) 
  

				
	 Objective

	  	Bonus Amount

	 Complete US Phase I Exherin Trial
	  	$	20,000
	 Complete Phase I/II Mesna Trial
	  	$	10,000
	 Complete Phase III STS Trial
	  	$	20,000
	 Meet requirements for NASDAQ listing of AHX stock
	  	$	10,000
	 Presentations of AHX results at ASCO meetings ($10 K each up to 3 maximum)
	  	$	30,000
	 Submit NDA for STS
	  	$	40,000
	 Initiate Phase II trial for Exherin
	  	$	10,000
	 Complete phase II trial for Exherin
	  	$	30,000
	 Initiate phase III trial for Exherin
	  	$	30,000
	 Achievement of major financing in excess of $10 M
	  	$	50,000
	 Stock price exceeds 3x 2003 year end price for at least one day
	  	$	25,000
	 Other board objectives and assessment of performance
	  	$	75,000

  
 Objectives for each subsequent year
will be established by November of the year and agreed to in writing. 
  

					
	 ConfidentialEXECUTIVE EMPLOYMENT AGREEMENT, DATED APRIL 21, 2004

 Exhibit 4.13 
  
 EMPLOYMENT AGREEMENT 
  

THIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of this 26th day of April 2004 (the “Effective Date”), by and between Adherex,
Inc. (the “Company”), a wholly owned subsidiary of Adherex Technologies Inc. (“AHX”), and James A. Klein, Jr., an individual residing at the address set forth on the signature page hereof (“Employee”). 
  
 1. Duties. While employed by the Company, Employee will be
employed in the position of Chief Financial Officer of the Company and of AHX (“CFO”), and, as such, Employee agrees to faithfully perform the duties of the position of CFO and to perform such other duties of an executive, managerial or
administrative nature as shall be specified and designated from time to time by the Chief Executive Officer of the Company. In addition, Employee will be responsible for periodically reporting to the Board of Directors and Audit Committee of AHX
(the “Board”). Employee agrees to perform his duties and responsibilities at the Company diligently and to the best of his ability, and further agrees to devote all of his business time and efforts to the performance of duties hereunder.
Employee further agrees not to be employed by any entity or other third party while employed by the Company without first obtaining the advance written consent of the Company. 
  
 2. Compensation. In consideration of his services to the Company, Employee will be compensated as follows:

  
 (a) Base Salary. Employee will be paid an annual base
salary of One Hundred Sixty Thousand Dollars (USD $160.000.00), less any withholdings required by law or properly requested by Employee (the “Base Salary”). The Company will pay Employee the Base Salary on its regularly scheduled paydays,
in accordance with its regular payroll practices and procedures. 
  
 (b) Signing Bonus. After Employee has executed this Agreement and any other required agreement(s), Employee will be paid a one-time lump sum signing bonus of Fifteen Thousand Dollars (USD $15,000.00) (the “Signing Bonus”).
The Signing Bonus is subject to any withholdings required by law and/or properly requested by Employee. 
  
 (c) Discretionary Bonus. In addition to the Base Salary and Signing Bonus, the Company in its sole discretion may award Employee an annual bonus of
no more than Fifty Thousand Dollars (USD S50,000.00) annually (the “Annual Bonus”). The Company will have the sole discretion and authority to determine Employee’s eligibility for and the amount of the Annual Bonus. The Annual Bonus
is subject to any withholdings required by law and/or properly requested by Employee. 
  
 (d) Stock Option Grant. Subject to the approval of its Board of Director (the “Board”), AHX further agrees to grant Employee an option to purchase up to One Million shares of AHX’s common stock
(the “Option”). The Option will be subject to the terms and conditions of the AHX Stock Option Plan (the “Plan”) and a separate stock option agreement between the Company and Employee. Shares subject to the Option will have an
exercise price equal to the fair market value on the date of grant, as determined by the Board. One-fourth of the shares subject to the Option will vest and be fully exercisable immediately after Employee has been 

 employed with the Company for ninety consecutive days. Thereafter, the remaining unvested shares will vest annually in
equal one-third installments over the next three years on the anniversary of your hire date for so long as Employee remains employed by the Company. As further detailed in the stock option agreement between the Company and Employee, if
Employee’s employment terminates due to a change in control of the Company (as defined in the stock option agreement), any then-remaining unvested shares shall immediately vest and be fully exercisable. 
  
 (e) Business Expenses. The Company will reimburse Employee for all
reasonable expenses incurred by Employee that are directly related to the business of the Company, provided that Employee complies with the Company’s policies and procedures for reimbursement or the advance of business expenses. 
  
 3. Benefits. While employed by the Company, Employee will
receive such other benefits as are provided from time to time to other similarly-situated employees of the Company. All such benefits are subject the terms and conditions of the plan documents by which such benefits are provided, and are subject to
change by the Company at any time, with or without advance notice. 
  
 4. Vacation and Paid Holidays. You will be eligible for vacation in accordance with the Company’s vacation policy. You will be entitled to take twenty (20) days of paid vacation annually. In addition, Employee will be
entitled to be paid for all holidays recognized by in accordance with Company policy. 
  
 5. Confidential Information and Restrictive Covenants. As a condition of Employee’s employment with the Company, Employee is required to sign the Confidentiality and intellectual Property Agreement
attached hereto as Exhibit A hereto (the “IP Agreement”), which includes Employee’s agreement to refrain from disclosing the Company’s confidential information and to refrain from engaging in certain competitive activities after
any termination of employment with the Company. The IP Agreement is fully incorporated into this Agreement by reference, and a breach of the IP Agreement will be construed as a breach of this Agreement. 
  
 6. Conflicts of Interest. You are subject to the Company’s
conflict of interest requirements and policies, and are responsible for recognizing and avoiding any and all circumstances that may give rise to an actual conflict of interest or give the appearance of a conflict of interest situation. 

 
 7. Termination of Employment. Employee’s employment
With the Company is at-will, meaning that either Employee or the Company can terminate the employment relationship at any time, for any or no reason, subject to the following provisions: 
  
 (a) Termination for Cause. Employee’s employment with the Company may be terminated for “Cause” at any
time and without advance notice. If terminated for Cause, Employee will only be entitled to receive payment of any wages and vacation pay earned or accrued to the date of termination. For purposes of this Agreement, “Cause” means
Employee’s: (I) material breach of the terms of this Agreement or the IP Agreement; (2) failure to diligently and properly perform his duties and responsibilities, or to comply with any policies and 
  

 2 

 directives of the Company or the Board; (3) dishonest or illegal action (including, without limitation, embezzlement) or
any other action whether or not dishonest or illegal by Employee that is materially detrimental to the interest and well-being of the Company, including ‘without limitation, harm to its reputation; (4) failure to fully disclose any material
conflict of interest he may have with the Company in a transaction involving the Company which conflict is materially detrimental to the interest of the Company; or (5) your conviction of (i) any felony or (ii) any misdemeanor or other crime of
moral turpitude (other than a minor traffic offense). 
  
 (b)
Termination upon Death or Disability. Employee’s employment with the Company will terminate immediately in the event of his death or permanent disability. For purposes of this Agreement, permanently disability means that Employee is
unable to perform the essential functions of his position, with or without a reasonable accommodation, for more than sixty (60) consecutive days or ninety (90) days in any 12-month period. if terminated pursuant to this Section 7(b), Employee or his
successor(s) will only be entitled to receive payment of any wages and vacation pay earned or accrued to the date of termination. 
  
 (c) Resignation by Employee. Employee may resign employment with the Company upon thirty (30) days’ advance written notice. If Employee fails
to provide at least thirty (30) days advance notice of resignation, Employee will forfeit payment for any accrued, unused vacation pay. The Company reserves the right in its sole discretion to pay Employee’s then-current Base Salary for all or
a part of such notice period, in lieu of Employee’s continued employment during the notice period. If Employee resigns his employment with the Company, Employee will be entitled to receive payment of any wages earned through the termination
date. 
  
 (d) Termination by the Company Without Cause.
Employee’s employment with the Company may be terminated at any time without Cause. The termination of Employee’s employment by the Company will be deemed to be “Without Cause” if Employee is terminated for any reason other than
Sections 7(a) through (c) of this Agreement. 
  
 8. Payments
upon Termination. 
  
 (a) Accrued Compensation. If
Employee’s employment with the company is terminated by either party for any reason, Employee will receive payment of any wages and vacation pay earned or accrued to the date of termination; provided, however, that if Employee resigns
his employment with the Company, he must provide the notice specified in Section 7(c) hereof in order to receive payment for any accrued, unused vacation time. 
  

(b) Severance Benefits. In addition to any accrued compensation, if Employee’s employment is terminated by the Company Without Cause, the
Company will provide Employee with the following severance benefits, subject to the conditions described below. 
  
 (1) If Employee is terminated by the Company Without Cause, the Company will continue paying Employee’s then-current Base Salary for a period of six
(6) months after the termination of Employee’s employment. 
  
 (2) In order to receive any portion of the severance benefits described in this Section 8(b), Employee will be required to first execute a release of all claims against the 
  

 3 

 Company, in form acceptable to the Company. In addition, to continue receiving the severance benefits, Employee must also
comply with any post-termination obligations to the Company as a result of the IP Agreement. 
  
 9. Notices. Any notice or other communication required or permitted hereunder must be made in writing and shall be delivered personally, sent by facsimile transmission or sent by certified, registered or
express mail, postage prepaid. Any such notice shall be deemed given when so delivered personally, sent by facsimile transmission or, if mailed, five days after the date of deposit in the United States mail as follows: 
  
 If to the Company, to: 
  
 Adherex, Inc. 
 2530 Meridian Parkway, Suite 200 
 Durham,
North Carolina 27713 
 Attention:     D. Scott Murray, Esq., General Counsel 
  
 with a copy to: 
  
 Wyrick Robbins Yates & Ponton, LLP 
 4101 Lake Boone Trail, Suite 300 
 Raleigh,
North Carolina 27607 
 Attention:     Donald R. Reynolds, Esq. 
  
 If to the Employee, at the address set forth on the signature page hereof.

  
 Any party may by notice given in accordance with this Section
9 to the other parties hereto designate another address or person for receipt by such person of notices hereunder. 
  
 10. Entire Agreement. This Agreement (including any exhibits attached hereto) contains the entire agreement between the parties with respect
to the subject matter hereof and supersedes all prior agreements, written or oral, with respect thereto, including without limitation any agreements that may have been entered into between the Company and Employee. 
  
 11. Waivers and Amendments. This Agreement may only be amended,
superseded, canceled, renewed or extended, and the terms hereof, may be waived, with a writing signed by all parties hereto, or, in the case of a waiver, by the party waiving compliance. No delay on the part of any party in exercising any right,
power or privilege hereunder shall operate as a waiver thereof nor shall any waiver on the part of any party of any such right, power or privilege nor any single or partial exercise of any such right, power or privilege, preclude any other or
further exercise thereof or the exercise of any other such right, power or privilege. 
  
 12. Governing Law; Venue. This Agreement will be governed by and construed in accordance with the laws of the state of North Carolina, without regard to conflicts of law principles. The parties further
agree that the state or federal courts sitting in Wake County, North Carolina shall have the sole and exclusive jurisdiction to hear any dispute(s) arising out of this Agreement (including any exhibits attached hereto). 
  

 4 

 13. Assignment. This Agreement, and Employee’s rights and obligations hereunder, may
not be assigned by Employee; any purported assignment by Employee in violation hereof shall be null and void. In the event of any sale, transfer or other disposition of all or substantially all of the Company’s assets or business, whether by
merger, consolidation or otherwise, Employee agrees that the Company may assign this Agreement and its rights and obligations hereunder to a successor in interest. 
  
 14. Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties and their
respective successors, permitted assigns, heirs, executors and legal representatives. 
  
 15. Counterparts. This Agreement may be executed by the parties hereto in separate counterparts, each of which when so executed and delivered shall be an original but all such counterparts together shall
constitute one and the same instrument. Each counterpart may consist of two copies hereof each signed by one of the parties hereto. 
  
 [Signature page follows] 
  

 5 

 IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the day and
year first above written. 
  

					
	 	 	ADHEREX, INC.
			
	 	 	By:	 	 /s/ Dr. William P. Peters

	 	 	 	 	Dr. William P. Peters, MD PhD MBA
	 	 	 	 	Chief Executive Officer
		
	 	 	EMPLOYEE
			
	 /s/

	 	 	 	 /s/ James A. Klein, Jr.

	Witness	 	Employee:	 	James A. Klein, Jr.
	 	 	 	 	320 Swans Mill Crossing
	 	 	 	 	Raleigh, North Carolina 27614

  

 6 

 Adherex. Inc. 
  
 EXHIBIT A 
  
 CONFIDENTIALITY, INTELLECTUAL 
 PROPERTY AND NONCOMPETITION AGREEMENT 
  
 THIS
CONFIDENTIALITY, INTELLECTUAL PROPERTY AND NONCOMPETITION AGREEMENT (the “Agreement”) dated this 26th day
of April 2004 is made between Adherex, Inc. (the “Company”) and James A. Klein, Jr. (“Employee”). 
  
 The parties hereto agree that it may be necessary for the Company to disclose to Employee from time to time certain confidential and proprietary
information concerning the products arid processes and technology developed by the Company and/or its affiliates or subsidiaries which the Company wishes to protect along with its trade secrets, technical expertise, business knowledge, procedures
and systems and all other confidential and proprietary information, together with proprietary and other information of a confidential nature provided by third parties, all of which is not generally available to the public, the unauthorized
disclosure of which would cause irreparable harm to the Company, its parent Adherex Technologies Inc., its affiliates or subsidiaries. 
  
 In consideration of my employment by the Company the undersigned and the Company agree as follows: 
  
 1. Definition of “Information”. For the purposes of this Agreement,
“Information” shall include, without limitation all or any part of the corporate, strategic or marketing plans, financial information, product information customer information, and other information relating to the business of the Company
its affiliates or subsidiaries, all research and development activities, all unpublished know-how, technical data, techniques, records, formulae, process, designs, sketches, photographs, plans, drawings, specifications, samples, reports, studies,
findings, inventions and ideas, whether patentable or not, whether they be trade secrets or not and whether they be in written, graphic or oral form, that are now or hereafter owned or acquired by Company, all of which are of a confidential and/or
proprietary nature concerning the development, testing, production and marketing of, and consulting in the area of products and processes and technology developed by Company, its affiliates or subsidiaries. Any Information which is communicated to
any person shall be stamped with the words “PROTECTED” or “CONFIDENTIAL” or other such identifying mark prior to its disclosure to such person. 
  
 2. Nondisclosure. Employee agrees to hold in trust and confidence all Information and to use and communicate any Information
only in the performance of his work for the Company to such authorized employees, subcontractors and others as are required by their duties to have knowledge thereof or for such other purposes and to such persons as are authorized by the Company in
writing. 
  
 3. Assignment of Intellectual Property Rights. All
improvements, inventions, know-how and discoveries, all Information and technology, and all patents or patent applications 

 arising out of or relating to the Information whether developed by the Employee or not during the term of the
Employee’s employment are the exclusive property of Company, its affiliates or subsidiaries. The Company, its affiliates or subsidiaries alone shall have the right to apply for, prosecute and obtain patents, copyrights, trademarks or industrial
design protection in any or all countries of the world in respect of any and all such improvements, inventions, know-how and discoveries and the Employee agrees to disclose, deliver and assign to the Company, its affiliates or subsidiaries, as the
case may be, all such improvements, inventions, know-how and discoveries whether patentable or not and agrees at any time to execute when requested any applications, transfers, assignments and other documents as necessary for the purpose of
confirming the Company’s, its affiliates’ or subsidiairies’ title, as the case may be, to any such improvements, inventions, know-how and discoveries, or for applying for prosecution and obtaining patents in any country with respect
thereto. Employee agrees to cooperate and assist fully in the prosecution of any such application. Any copyrightable materials generated or developed by Employee while employed by the Company, including but not limited to, computer programs and
related documentation, belong to the Company and Employee hereby assigns to the Company all interest and ownership in such copyright as and when created. 
  
 4. Restrictive Covenants. 
  
 (a) Noncompetition; Nonsolicitation. While employed by the Company and for six months after the termination of his employment with the Company by
either party, for any reason whatsoever, Employee will not, without the prior written consent of the Company: 
  
 (1) provide financial-related services to, manage, control, or participate in the management or control of any direct competitor of the Company that is
located in the Restricted Territory (as defined below) and is engaged in the Company’s Business (as defined below); 
  
 (2) solicit or attempt to solicit for the purpose of selling products comparable to or in competition with those products sold by the Company to any
customers or clients of the Company with whom Employee had business contacts on behalf of the Company during his employment with the Company; 
  
 (3) interfere or attempt to interfere with any contracts or agreements that the Company has with any customers, vendors or suppliers; and/or 

 
 (4) solicit any employees of the Company (i) to resign their employment
with the Company; (ii) to violate any duties owed to the Company; or (iii) breach any agreements with the Company. 
  
 Employee agrees not to engage in any of the foregoing activities set out in this Section 4(a) directly or indirectly acting alone or as a director,
employee, agent, consultant, member of a partnership, firm, company or other entity or as a holder of or investor in more than 2% of any security of any class of any company or other business entity. 
  
 (b) Restricted Territory. For purposes of this Agreement, the
“Restricted Territory” shall mean the greater metropolitan areas of: 
  

	 	(i)	Boston, MA; 

	 	(ii)	New York, NY; 

	 	(iii)	Philadelphia, PA; 

	 	(iv)	Princeton, NJ; 

	 	(v)	Indianapolis, IN; 

	 	(vi)	Groton, CT; 

	 	(vii)	Chicago, IL; 

	 	(viii)	Seattle, WA; and 

	 	(ix)	any locality within a thirty-five mile radius of Raleigh/Durham, North Carolina and/or Bethesda, MD. 

  
 (c) Company’s “Business”. The parties hereto agree that the Company’s Business” is
researching, developing, marketing and selling pharmaceutical products and therapies related to the tumor vascular targeting platform. 
  
 (d) Enforceability. The parties hereto agree that in the event that the length of time, the geographic area or prohibited activities set forth in
this Section 4 shall be deemed too restrictive in any court proceeding, that the court shall reduce such restrictions to those which it deems reasonable and enforceable under the circumstances. 
  
 5. Return of Company Property. Upon demand by the Company or no later than the
termination of his employment, Employee agrees to immediately return to the Company any Information or other Company property in his possession. Such Information and any other Company property will be returned to the Company in the same condition as
when provided to Employee, reasonable wear and tear excepted. Employee further agrees to allow the Company to inspect any documents or work produced relating to the Information that are in the possession or control of the Employee. The Employee
agrees that unless authorized by the Company or as necessary in performing his job duties and responsibilities, he will not copy the information. 
  
 6. Injunctive Relief. In the event that Employee breached the provisions of Section 1 through 5 of this Agreement, the parties hereto agree that such breach
could not be adequately remedied by monetary damages. Therefore, the parties agree that in addition to any other remedies available for such breach, the Company will be entitled to injunctive relief for Employee’s breach or threatened breach of
Sections 1 through 5 of this Agreement in order to prevent or restrict any further breach or threatened breach. A failure by the Company to enforce any provision of this Agreement does not constitute a waiver of any of its rights and does not
release the Employee of any responsibility for performance under this Agreement. 
  
 7. Limitations. The Company agrees that all the obligations of confidentiality and non-disclosure terminate when the Employee can establish with documentary proof that all the Information: 
  
 (a) was in the public domain at the time of the disclosure to the Employee
by the Company, its affiliates or subsidiaries, 
  
 (b) entered
the public domain through no fault of the Employee, 

 (c) was in the Employee’s possession free of any obligation of confidentiality before disclosure by
the Company, its affiliates or subsidiaries to the Employee, or 
  
 (d) was disclosed to Employee in good faith by a third party which has the right to make such disclosure, 
  
 provided that the Employee notifies the Company in writing within 10 days of receipt of the Information where the exemptions under (c) and (d) apply. 
  
 8. Survival. The obligations of Employee pursuant to Sections 1 through 5 of
this Agreement will continue in full force and effect notwithstanding termination of the employment of the Employee. 
  
 9. No Other Agreements. Employee hereby advises the Company that unless described in writing on Schedule “A” attached hereto, he is not bound by
any other confidentiality, non-disclosure, noncompetition or non-solicitation agreements. Employee further agrees not to become a party to any such agreement with others during his employment. The Employee further advises the Company that there are
no patents, patent applications or other inventions made by the Employee prior to his employment with the Company unless any are specifically listed on Schedule “B” hereto. If no Schedules are attached to this Agreement, then there are no
such agreements or patents outstanding. 
  
 10. Governing Law;
Venue. The parties hereto agree that this Agreement is to be interpreted and governed by the laws of the state of North Carolina. The parties further agree that the state or federal courts sitting in Wake County, North Carolina shall have
the sole and exclusive jurisdiction to hear any dispute(s) arising out of this Agreement. 
  
 11. Severability. The various sections of this Agreement are severable and the invalidity of one does not affect the enforceability of the other provisions of this Agreement. 
  
 12. Miscellaneous. For ease of interpretation, this Agreement is to be read
with all changes in gender and number as the circumstances require and the Agreement is binding upon and available to the benefit of both parties, their personal representatives, successors, affiliates, subsidiaries and assigns. Employee expressly
agrees that the Company may assign its rights and obligations hereunder to any successor in interest. Any notice under this Agreement should be delivered to the Company’s head office and the Employee at his home address. 
  
 [Signature page follows] 

 IN WITNESS WHEREOF the parties have executed this Confidentiality and Intellectual Property on the day
and year first written above. 
  

					
	 	 	ADHEREX, INC.
			
	 	 	By:	 	 /s/ Dr. William P. Peters

	 	 	 	 	Dr. William P. Peters
	 	 	 	 	Chief Executive Officer
			
	 /s/

	 	 	 	 /s/ James A. Klein, Jr.

	Witness	 	Employee:	 	James A. Klein, Jr.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]